BioSpace News Archive

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its third quarter fiscal 2023 results.

After receiving commercial approval from the FDA in mid-August 2023, Pfizer’s elranatamab became the latest bispecific antibody to be approved.

Soleno Therapeutics, Inc. today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023.

PDS Biotechnology Corporation today announced that data from the IMMUNOCERV Phase 2 clinical trial investigating PDS0101 in combination with standard-of-care chemoradiotherapy (CRT) for the treatment of locally advanced cervical cancer will be featured in an oral presentation at the American Society for Radiation Oncology (ASTRO 2023) Annual Meeting.

Mustang Bio, Inc. today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia

Day One Biopharmaceuticals today announced it has entered into an exclusive, worldwide license agreement and research collaboration with Sprint Bioscience for its VRK1 program.

RVL Pharmaceuticals plc today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares.

Baudax Bio, Inc. today announced results for the three and six months ended June 30, 2023 and provided a business update.

Core Biotherapeutics has entered into a collaboration with the University of Colorado Anschutz Medical Campus (CU Anschutz) to expand the benefits of their therapeutic approach to Acute Myeloid Leukemia (AML) patients.

Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK ® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis.